Comparison of surgical treatment versus transcatheter arterial chemoembolization combined with systemic treatment for spontaneously ruptured hepatocellular carcinoma Authors: Jianwei Liu, Xiaorong Pan, Shilei Bai, Caixia Lu, Chunmei Li, Liu Liu, Jian Zhai, Hui Xue, Yong Xia, Kui Wang Published: 2026 ABSTRACT Background and aimsThis study aimed to evaluate the efficacy of hepatectomy versus transcatheter arterial chemoembolization (TACE), both combined with targeted therapy and immunotherapy, in patients with spontaneously ruptured hepatocellular carcinoma (HCC).MethodsWe retrospectively reviewed the data of 78 patients with spontaneously ruptured HCC. Patients received targeted therapy and immunotherapy and were stratified into the hepatectomy group (n = 43) or TACE group (n = 35) based on the local treatment modality. Postoperative complications and long-term prognosis were compared.ResultsMultivariable analysis identified TACE (hazard ratio [HR]: 3.394, 95% confidence interval [CI]: 1.777–6.483 for overall survival [OS]; HR: 4.763, 95% CI: 2.601–8.723 for event-free survival [EFS] and vascular invasion (VI) (HR: 3.141, 95% CI: 1.554–6.346 for OS; HR: 3.277, 95% CI: 1.713–6.269 for EFS) as independent risk factors for OS and EFS. An AFP level > 400 ng/mL (HR: 1.944, 95% CI: 1.075–3.518) was identified as an independent risk factor for EFS. The 1-, 3-, and 5-year OS rates for the hepatectomy and TACE groups were 88.4%, 53.9%, and 31.8% and 71.4%, 22.9%, and NA (p = 0.001), respectively, and the 1-, 3-, and 5-year EFS rates were 72.1%, 26.3%, and 23.0% and 45.7%, 0%, and 0% (p < 0.001). Multivariable analysis following propensity score matching showed that TACE, VI, and AFP > 400 ng/mL remained independent risk factors for OS and EFS. The incidence of complications associated with hepatectomy was significantly lower than that associated with TACE (p = 0.031). There were no significant differences between the groups regarding Grade III/IV complications related to hepatectomy or TACE or any grade or Grade III/IV complications related to targeted therapy and immunotherapy (p > 0.05).ConclusionsCompared with TACE combined with targeted therapy and immunotherapy, hepatectomy combined with targeted therapy and immunotherapy is a safe and effective treatment for patients with spontaneously ruptured HCC. It does not increase the incidence of complications and offers improved long-term prognosis. Introduction Primary liver cancer is the most common malignancy of the gastrointestinal tract. It ranks as the seventh most frequently diagnosed cancer worldwide and is associated with high mortality rates.1 Some hepatocellular carcinomas (HCCs) are prone to spontaneous rupture and hemorrhage because of the large size of the tumor or its proximity to the liver capsule. Ruptured HCC accounts for less than 3% of all HCC cases in Western countries and up to 26% in Eastern countries.2,3 The American Joint Committee on Cancer/Union for International Cancer Control defines ruptured HCC as a T4 lesion, staging it similarly to tumors with vascular or bile duct invasion.4,5 Patients have a high mortality rate following rupture, with reported mortality after spontaneous rupture reaching as high as 16%–30%.6 The long-term prognosis of these patients is significantly worse than that of HCC patients without spontaneous rupture,7,8 with a reported 5-year overall survival (OS) rate of only 20%.9 Treatment modalities for spontaneously ruptured HCC include transcatheter arterial embolization (TAE), emergency hepatectomy, and staged hepatectomy.10,11 Most researchers suggest intra-arterial embolization combined with staged hepatectomy to improve the long-term prognosis of patients with spontaneously ruptured HCC.12,13 With the increasing clinical application of targeted therapy and immunotherapy, the prognosis of HCC has improved significantly.14 However, the comparative efficacy of hepatectomy versus transcatheter arterial chemoembolization (TACE), both combined with targeted therapy and immunotherapy, for spontaneously ruptured HCC is unknown. In this study, we analyzed 78 patients with spontaneously ruptured HCC who underwent hepatectomy or TACE combined with targeted therapy and immunotherapy to evaluate the differences between these two treatment approaches. Patients and methods Patients We retrospectively reviewed data from 78 patients with spontaneously ruptured HCC treated at our hospital (Eastern Hepatobiliary Surgery Hospital) between January 2019 and July 2022. All patients were initially admitted to a local hospital for emergency TAE to control bleeding and prevent hemorrhagic shock. After screening using inclusion and exclusion criteria, detailed clinicopathological data were recorded. The inclusion criteria were as follows: (1) adult patients (≥18 years) with HCC confirmed by pathological assessment or non-invasive assessment following the American Association for the Study of Liver Diseases criteria;15 (2) age ≤ 75 years; (3) Eastern Cooperative Oncology Group performance status of 0–2; (4) Child–Pugh grade A or B7 prior to surgery or TACE; (5) preoperative evaluation indicated that the patient was eligible for radical surgical resection; (6) no history of other malignancies; and (7) provided written informed consent. For patients undergoing hepatectomy, an additional criterion was required: (8) complete tumor resection with negative surgical margins. The exclusion criteria were as follows: (1) receipt of other anti-tumor therapies prior to TAE; (2) incomplete clinical data; (3) poor general condition or inability to tolerate hepatectomy or TACE; (4) postoperative pathology confirming intrahepatic cholangiocarcinoma or mixed HCC; (5) presence of extrahepatic metastases (6) concomitant intraoperative procedures (e.g., biliary-enteric anastomosis); that could affect postoperative complications; and (7) loss to follow-up within 1 month after hepatectomy or TACE. Preoperative examination, hepatectomy, TACE, and targeted therapy and immunotherapy Before treatment, patients underwent evaluation to assess general status, liver function, feasibility and tolerability of TACE and hepatectomy, and tumor resectability. Preoperative assessments included routine blood tests, liver and kidney function, coagulation profiles, tumor markers, hepatitis markers, blood typing, electrocardiogram, lung function, gastroscopy, chest computed tomography, abdominal ultrasound, and liver magnetic resonance imaging. Patients deemed able to tolerate hepatectomy and who consented to the procedure underwent surgical treatment. Hepatectomy was performed via anatomical or non-anatomical resection to ensure complete tumor removal. Hemostasis was achieved in the operative area, followed by thorough peritoneal lavage with normal saline. Adjuvant TACE was routinely performed after hepatectomy. For TACE, angiography was used to identify tumor-feeding arteries, followed by the injection of lipiodol and chemotherapeutic agents (pirarubicin, hydroxycamptothecin). The arteries were then embolized using microspheres and/or gelatin sponge particles.16 This induces tumor necrosis as a result of ischemia and the chemotherapeutic effect. TACE was generally performed on an as-needed basis. Adjuvant TACE, similar to conventional TACE, was typically conducted 4 weeks post-surgery.17 Using the Seldinger technique, a catheter was inserted into the proper hepatic artery via the femoral artery to administer adjuvant TACE to the remnant liver. Lipiodol was injected, and if no tumor staining was observed, a mixture of chemotherapeutic agents (pirarubicin, hydroxycamptothecin) was administered to the remaining liver.17,18 All patients received targeted therapy combined with immunotherapy. Targeted therapy regimens included sorafenib (400 mg orally twice daily) or lenvatinib (12 mg/day for body weight ≥ 60 kg; 8 mg/day for body weight < 60 kg) administered orally once daily until disease recurrence, progression, serious adverse events, or withdrawal of consent. Dose reductions or interruptions were permitted to manage toxicity (sorafenib reduced to 200 mg twice daily, then 200 mg once daily; lenvatinib reduced to 8 mg, then 4 mg once daily).19 Immunotherapy consisted of programmed cell death protein 1 (PD-1) inhibitors, such as tislelizumab, sintilimab and so on, at a standard dose of 200 mg intravenously every 3 weeks. Follow-up and endpoints Follow-up was conducted every 2–3 months for the hepatectomy group and every 2 months for the TACE group. In the hepatectomy group, patients with recurrence were managed with repeat hepatectomy, ablation, or TACE depending on tumor characteristics. In the TACE group, TACE and second-line targeted agents were administered upon tumor progression. The primary endpoints were overall survival (OS) and event-free survival (EFS). OS was defined as the time from the first treatment to death or loss to follow-up. EFS was defined as the time from the first treatment to tumor recurrence, metastasis, or death (for the hepatectomy group) or to tumor progression or death (for the TACE group), whichever occurred first. The secondary endpoint was complications. These were categorized as overall complications (including adverse events from hepatectomy, TACE, or targeted therapy and immunotherapy), complications specifically associated with hepatectomy or TACE, and complications associated with targeted therapy and immunotherapy that occurred during the treatment period.20,21 Statistical analysis Statistical analyses were performed using SPSS software, version 26 (SPSS Inc., Chicago, IL, USA) and R software, version 4.0.0 (http://www.R-project.org). Continuous variables are presented as medians (ranges), and differences between groups were compared using independent samples t-tests or Mann–Whitney U tests, as appropriate. Categorical variables are reported as frequencies (percentages) and were compared using the chi-square test or Fisher's exact test. OS and EFS curves were generated using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards regression analyses were conducted to identify independent risk factors for OS and EFS. Variables with a p-value < 0.10 in the univariate analysis were included in the multivariate analysis.22 Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate relative risks. A two-sided p-value < 0.05 indicated statistical significance. Results Patient characteristics Fig. 1 shows the flow chart of the study. Table 1 presents the baseline clinicopathological data of the 78 patients with spontaneously ruptured HCC included in this study. Patients were stratified into the hepatectomy group (n = 43) and the TACE group (n = 35). Compared with the TACE group, the hepatectomy group had a lower proportion of patients with positive hepatitis B e-antigen (62.8% vs. 85.7%, p = 0.023), lower median levels of alanine aminotransferase (ALT) (23.5 vs. 27.8 IU/L, p = 0.044), and lower median levels of aspartate aminotransferase (AST) (22.5 vs. 28.1 IU/L, p = 0.045). There were no significant differences in other clinicopathological characteristics between the two groups.Fig. 1The flow chart of the study.Table 1Characteristics of patients in the overall and PSM cohorts.Table 1Variableoverall cohort, Number (%)/median (range)pAfter PSM, Number (%)/median (range)pHepatectomy group (n = 43)TACE group (n = 35)Hepatectomy group (n = 35)TACE group (n = 35)Non‒operative characteristicsSex, male34 (79.1)28 (80.0)0.91926 (74.3)28 (80.0)0.569Age, years55.0 (34.0‒71.0)58.0 (35.0‒69.0)0.43654.0 (34.0‒71.0)58.0 (35.0‒69.0)0.118BMI, ≥24 kg/m224 (55.8)20 (57.1)0.90619 (54.3)20 (57.1)0.810ECOG score, 121 (48.8)20(57.1)0.46518 (51.4)20 (57.1)0.631Diabetes, yes5 (11.6)3(8.6)0.9465 (14.3)3 (8.6)0.707HBsAg, positive33 (76.7)31 (88.6)0.17626 (74.3)31 (88.6)0.124HBeAg, positive27 (62.8)30 (85.7)0.02325 (71.4)30 (85.7)0.145HCV, positive2 (4.7)3 (8.6)0.81232 (91.4)32 (91.4)1.000Child‒Pugh, A39 (90.7)32 (91.4)1.00014 (40.0)17 (48.6)0.470HBV‒DNA level, > 2000 IU/mL16 (37.2)17 (48.6)0.3121 (2.9)4 (11.4)0.353Preoperative antiviral therapy, yes1 (2.3)4 (11.4)0.2431 (2.9)3 (8.6)0.607NLR > 2.5027 (62.8)22 (62.9)0.99513.7 (4.4‒51.6)12.6 (5.8‒70.0)0.846TBIL, μmol/L13.9 (4.4‒51.6)12.6 (5.8‒70.0)0.76341.6 (33.4‒49.8)42.0 (36.0‒51.0)0.911ALB, g/L42.3 (33.4‒49.8)42.0 (36.0‒51.0)0.95624.4 (13.0‒44.5)27.8 (13.2‒74.0)0.139ALT, U/L23.5 (12.3‒57.5)27.8 (13.2‒74.0)0.04423.0 (9.5‒61.4)28.1 (5.0‒86.4)0.105AST, U/L22.5 (9.5‒61.4)28.1 (5.0‒86.4)0.04511.6 (10.2‒15.2)11.7 (10.2‒13.3)0.892PT, s11.6 (9.5‒15.2)11.7 (10.2‒13.3)0.710135.0 (10.2‒15.2)11.7 (10.2‒13.3)0.634HGB, g/L134.0 (73.0‒177.0)133.0 (98.0‒168.0)0.763141.5 (73.0‒177.0)133.0 (98.0‒168.0)0.202PLT, 109/L173.0 (75.0‒381.0)220.0 (61.0‒439.0)0.04122 (62.9)22 (62.9)1.000AFP, ng/mL110.0 (1.6‒570000.0)800.0 (2.3‒739000.0)0.226629.0 (1.8‒570000.0)800.0 (2.3‒739000.0)0.756AFP, > 400 ng/mL20 (46.5)21 (60.0)0.23519 (54.3)21 (60.0)0.629Tumor diameter∗, cm7.9 (3.5‒13.1)8.0 (3.5‒14.1)0.2567.6 (3.5‒13.1)8.0 (3.5‒14.1)0.200Tumor number∗, multiple†9 (20.9)12 (34.3)0.1867 (20.0)12 (34.3)0.179VI∗, presence9 (20.9)9 (25.7)0.6187 (20.0)9 (25.7)0.569Cirrhosis∗, yes30 (69.8)25 (71.4)0.87323 (65.7)25 (71.4)0.607Intraoperative characteristicsOperation time, hours2.1 (1.0‒5.3)2.0 (1.0‒5.3)Hepatectomy, anatomic6 (14.0)6 (17.1)Major hepatectomy, yes17 (39.5)13 (37.1)Intraoperative bleeding, mL300 (100‒1500)200 (100‒1500)Intraoperative transfusion, yes10 (23.3)7 (20.0)Abbreviations: AFP, alpha fetoprotein; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e‒antigen; HBV‒DNA, hepatitis B virus deoxyribonucleic acid; HCV, hepatitis C virus; HGB, hemoglobin; NLR, neutrophil to lymphocyte ratio; PLT, platelet; PSM, propensity score‒matched; PT, prothrombin time; TACE, transarterial chemoembolization; TBIL, total bilirubin; VI, vascular invasion.∗: Based on pre‒treatment imaging studies.†: Tumor nodules ≥ 2. The flow chart of the study. Table 1Characteristics of patients in the overall and PSM cohorts.Table 1Variableoverall cohort, Number (%)/median (range)pAfter PSM, Number (%)/median (range)pHepatectomy group (n = 43)TACE group (n = 35)Hepatectomy group (n = 35)TACE group (n = 35)Non‒operative characteristicsSex, male34 (79.1)28 (80.0)0.91926 (74.3)28 (80.0)0.569Age, years55.0 (34.0‒71.0)58.0 (35.0‒69.0)0.43654.0 (34.0‒71.0)58.0 (35.0‒69.0)0.118BMI, ≥24 kg/m224 (55.8)20 (57.1)0.90619 (54.3)20 (57.1)0.810ECOG score, 121 (48.8)20(57.1)0.46518 (51.4)20 (57.1)0.631Diabetes, yes5 (11.6)3(8.6)0.9465 (14.3)3 (8.6)0.707HBsAg, positive33 (76.7)31 (88.6)0.17626 (74.3)31 (88.6)0.124HBeAg, positive27 (62.8)30 (85.7)0.02325 (71.4)30 (85.7)0.145HCV, positive2 (4.7)3 (8.6)0.81232 (91.4)32 (91.4)1.000Child‒Pugh, A39 (90.7)32 (91.4)1.00014 (40.0)17 (48.6)0.470HBV‒DNA level, > 2000 IU/mL16 (37.2)17 (48.6)0.3121 (2.9)4 (11.4)0.353Preoperative antiviral therapy, yes1 (2.3)4 (11.4)0.2431 (2.9)3 (8.6)0.607NLR > 2.5027 (62.8)22 (62.9)0.99513.7 (4.4‒51.6)12.6 (5.8‒70.0)0.846TBIL, μmol/L13.9 (4.4‒51.6)12.6 (5.8‒70.0)0.76341.6 (33.4‒49.8)42.0 (36.0‒51.0)0.911ALB, g/L42.3 (33.4‒49.8)42.0 (36.0‒51.0)0.95624.4 (13.0‒44.5)27.8 (13.2‒74.0)0.139ALT, U/L23.5 (12.3‒57.5)27.8 (13.2‒74.0)0.04423.0 (9.5‒61.4)28.1 (5.0‒86.4)0.105AST, U/L22.5 (9.5‒61.4)28.1 (5.0‒86.4)0.04511.6 (10.2‒15.2)11.7 (10.2‒13.3)0.892PT, s11.6 (9.5‒15.2)11.7 (10.2‒13.3)0.710135.0 (10.2‒15.2)11.7 (10.2‒13.3)0.634HGB, g/L134.0 (73.0‒177.0)133.0 (98.0‒168.0)0.763141.5 (73.0‒177.0)133.0 (98.0‒168.0)0.202PLT, 109/L173.0 (75.0‒381.0)220.0 (61.0‒439.0)0.04122 (62.9)22 (62.9)1.000AFP, ng/mL110.0 (1.6‒570000.0)800.0 (2.3‒739000.0)0.226629.0 (1.8‒570000.0)800.0 (2.3‒739000.0)0.756AFP, > 400 ng/mL20 (46.5)21 (60.0)0.23519 (54.3)21 (60.0)0.629Tumor diameter∗, cm7.9 (3.5‒13.1)8.0 (3.5‒14.1)0.2567.6 (3.5‒13.1)8.0 (3.5‒14.1)0.200Tumor number∗, multiple†9 (20.9)12 (34.3)0.1867 (20.0)12 (34.3)0.179VI∗, presence9 (20.9)9 (25.7)0.6187 (20.0)9 (25.7)0.569Cirrhosis∗, yes30 (69.8)25 (71.4)0.87323 (65.7)25 (71.4)0.607Intraoperative characteristicsOperation time, hours2.1 (1.0‒5.3)2.0 (1.0‒5.3)Hepatectomy, anatomic6 (14.0)6 (17.1)Major hepatectomy, yes17 (39.5)13 (37.1)Intraoperative bleeding, mL300 (100‒1500)200 (100‒1500)Intraoperative transfusion, yes10 (23.3)7 (20.0)Abbreviations: AFP, alpha fetoprotein; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e‒antigen; HBV‒DNA, hepatitis B virus deoxyribonucleic acid; HCV, hepatitis C virus; HGB, hemoglobin; NLR, neutrophil to lymphocyte ratio; PLT, platelet; PSM, propensity score‒matched; PT, prothrombin time; TACE, transarterial chemoembolization; TBIL, total bilirubin; VI, vascular invasion.∗: Based on pre‒treatment imaging studies.†: Tumor nodules ≥ 2. Characteristics of patients in the overall and PSM cohorts. Abbreviations: AFP, alpha fetoprotein; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e‒antigen; HBV‒DNA, hepatitis B virus deoxyribonucleic acid; HCV, hepatitis C virus; HGB, hemoglobin; NLR, neutrophil to lymphocyte ratio; PLT, platelet; PSM, propensity score‒matched; PT, prothrombin time; TACE, transarterial chemoembolization; TBIL, total bilirubin; VI, vascular invasion. ∗: Based on pre‒treatment imaging studies. †: Tumor nodules ≥ 2. OS and EFS in the overall cohort The median follow-up duration for the 78 patients was 40.0 months. The 1-, 3-, and 5-year OS and EFS rates for the overall cohort were 80.8%, 40.1%, and 23.0% and 60.3%, 14.5%, and 12.7%, respectively. The results of the univariate analysis for OS are shown in Supplementary Table 1. Variables with a p-value < 0.10 in the univariate Cox analysis were included in the multivariate Cox analysis. Multivariate analysis revealed that TACE (HR: 3.394, 95% CI: 1.777–6.483), AFP > 400 ng/mL (HR: 1.944, 95% CI: 1.075–3.518), and vascular invasion (VI) (HR: 3.141, 95% CI: 1.554–6.346) were independent risk factors for OS (Table 2). The 1-, 3-, and 5-year OS rates for the hepatectomy and TACE groups were 88.4%, 53.9%, and 31.8% and 71.4%, 22.9%, and NA, respectively (p = 0.001) (Fig. 2A).Table 2Multivariable analysis of OS and EFS in the overall and PSM cohorts.Table 2VariableOSEFSpHR95%CIpHR95%CIBefore PSMTreatments, TACE vs. hepatectomy< 0.0013.3941.777‒6.483< 0.0014.7632.601‒8.723HBV‒DNA, IU/mL, > 2000 vs. ≤ 20000.2931.4410.730‒2.8460.2691.4180.764‒2.631AFP, ng/mL, > 400 vs. ≤ 4000.0281.9441.075‒3.5180.0641.6590.972‒2.832Tumor diameter∗, cm, > 5 vs. ≤ 50.6611.1930.543‒2.6190.6670.8560.422‒1.736VI∗, presence vs. absence0.0013.1411.554‒6.346< 0.0013.2771.713‒6.269After PSMTreatments, TACE vs. hepatectomy< 0.0014.6812.235‒9.807< 0.0015.7852.899‒11.546HBeAg, positive vs. negative———0.0732.0040.936‒4.288HBV‒DNA, IU/mL, > 2000 vs. ≤ 20000.2701.5150.724‒3.1710.8811.0550.525‒2.118AFP, ng/mL, > 400 vs. ≤ 4000.0102.4051.238‒4.6730.0152.1361.161‒3.930Tumor diameter∗, cm, > 5 vs. ≤ 50.9491.0290.434‒2.4410.8800.9410.431‒2.056VI∗, presence vs. absence0.0033.2051.505‒6.827< 0.0014.5782.117‒9.898Abbreviations: PSM, propensity score-matched; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; TACE, transarterial chemoembolization; HBeAg, hepatitis B e‒antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, alpha fetoprotein; VI, vascular invasion.∗: Based on pre‒treatment imaging studies.†: Tumor nodules ≥ 2.Fig. 2Kaplan–Meier estimate of overall survival (OS) and event-free survival (EFS) for hepatectomy group and transcatheter arterial chemoembolization (TACE) group in the overall group of patients with hepatocellular carcinoma (HCC) and propensity score matching (PSM) cohort. Kaplan–Meier estimate of OS (A) and EFS (B) for HCC patients underwent hepatectomy group and TACE group in the overall group; Kaplan–Meier estimate of OS (C) and EFS (D) for HCC patients underwent hepatectomy group and TACE group in the PSM group. Table 2Multivariable analysis of OS and EFS in the overall and PSM cohorts.Table 2VariableOSEFSpHR95%CIpHR95%CIBefore PSMTreatments, TACE vs. hepatectomy< 0.0013.3941.777‒6.483< 0.0014.7632.601‒8.723HBV‒DNA, IU/mL, > 2000 vs. ≤ 20000.2931.4410.730‒2.8460.2691.4180.764‒2.631AFP, ng/mL, > 400 vs. ≤ 4000.0281.9441.075‒3.5180.0641.6590.972‒2.832Tumor diameter∗, cm, > 5 vs. ≤ 50.6611.1930.543‒2.6190.6670.8560.422‒1.736VI∗, presence vs. absence0.0013.1411.554‒6.346< 0.0013.2771.713‒6.269After PSMTreatments, TACE vs. hepatectomy< 0.0014.6812.235‒9.807< 0.0015.7852.899‒11.546HBeAg, positive vs. negative———0.0732.0040.936‒4.288HBV‒DNA, IU/mL, > 2000 vs. ≤ 20000.2701.5150.724‒3.1710.8811.0550.525‒2.118AFP, ng/mL, > 400 vs. ≤ 4000.0102.4051.238‒4.6730.0152.1361.161‒3.930Tumor diameter∗, cm, > 5 vs. ≤ 50.9491.0290.434‒2.4410.8800.9410.431‒2.056VI∗, presence vs. absence0.0033.2051.505‒6.827< 0.0014.5782.117‒9.898Abbreviations: PSM, propensity score-matched; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; TACE, transarterial chemoembolization; HBeAg, hepatitis B e‒antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, alpha fetoprotein; VI, vascular invasion.∗: Based on pre‒treatment imaging studies.†: Tumor nodules ≥ 2. Multivariable analysis of OS and EFS in the overall and PSM cohorts. Abbreviations: PSM, propensity score-matched; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; TACE, transarterial chemoembolization; HBeAg, hepatitis B e‒antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, alpha fetoprotein; VI, vascular invasion. ∗: Based on pre‒treatment imaging studies. †: Tumor nodules ≥ 2. Kaplan–Meier estimate of overall survival (OS) and event-free survival (EFS) for hepatectomy group and transcatheter arterial chemoembolization (TACE) group in the overall group of patients with hepatocellular carcinoma (HCC) and propensity score matching (PSM) cohort. Kaplan–Meier estimate of OS (A) and EFS (B) for HCC patients underwent hepatectomy group and TACE group in the overall group; Kaplan–Meier estimate of OS (C) and EFS (D) for HCC patients underwent hepatectomy group and TACE group in the PSM group. The results of the univariate analysis for EFS are shown in Supplementary Table 1. Variables with a p < 0.10 were included in the multivariate Cox analysis (Table 2). The results identified TACE (HR: 4.763, 95% CI: 2.601–8.723) and VI (HR: 3.277, 95% CI: 1.713–6.269) as independent risk factors for EFS. The 1-, 3-, and 5-year EFS rates for the hepatectomy and TACE groups were 72.1%, 26.3%, and 23.0% and 45.7%, 0%, and 0%, respectively (p < 0.001) (Fig. 2B). OS and EFS in the propensity score-matched (PSM) cohort After PSM, 70 patients (including 35 patients in the hepatectomy group and 35 in the TACE group) were selected for further analysis. There were no significant differences in clinicopathological characteristics between these two groups (Table 1). The results of the univariate analysis for these 70 patients are shown in Supplementary Table 2. Variables with a p-value < 0.10 in the univariate analysis were included in the multivariate analysis (Table 2). The results showed that TACE (HR: 4.681, 95% CI: 2.235–9.807), AFP > 400 ng/mL (HR: 2.405, 95% CI: 1.238–4.673), and VI (HR: 3.205, 95% CI: 1.505–6.827) were independent risk factors for OS. The 1-, 3-, and 5-year OS rates for the hepatectomy and TACE groups were 88.6%, 61.4%, and 34.4% and 71.4%, 22.9%, and NA, respectively (p < 0.001) (Fig. 2C). The results of the univariate analysis for EFS are shown in Supplementary Table 2. Variables with a p-value < 0.10 in the univariate analysis were included in the multivariate analysis (Table 2). The results demonstrated that TACE (HR: 5.785, 95% CI: 2.899–11.546), AFP > 400 ng/mL (HR: 2.136, 95% CI: 1.161–3.930), and VI (HR: 4.578, 95% CI: 2.117–9.898) were independent risk factors for EFS. The 1-, 3-, and 5-year EFS rates for the hepatectomy and TACE groups were 74.3%, 27.1%, and 23.3% and 45.7%, 0%, and 0%, respectively (p < 0.001) (Fig. 2D). Patterns of recurrence or metastasis Table 3 shows the types and sites of recurrence or metastasis in the hepatectomy group of the overall cohort. Among patients with tumor recurrence, 19 had intrahepatic recurrence only, 4 had intrahepatic recurrence combined with abdominal lymph node metastasis, 2 had intrahepatic recurrence combined with peritoneal dissemination, 1 had peritoneal dissemination combined with abdominal lymph node metastasis, 1 had intrahepatic recurrence combined with abdominal lymph node and pulmonary metastases, 1 had abdominal lymph node metastasis combined with pulmonary metastasis, 3 had pulmonary metastases, and 2 had recurrence or metastasis at uncertain sites.Table 3Patterns of recurrence or metastasis.Table 3ParameterHepatectomy group (n = 43)Total recurrence or metastasis, na32Types of recurrence or metastasiss, na Intrahepatic only19 Extrahepatic only4 Intrahepatic plus extrahepatic7 Uncertain2Site of recurrence or metastasiss, nab Intrahepatic recurrence26 Peritoneal spread3 Abdominal lymph node metastasis7 Pulmonary metastasis5 Uncertain24 patients had intrahepatic recurrence plus abdominal lymph node metastasis.2 patients had intrahepatic recurrence plus peritoneal spread.1 patient had peritoneal spread plus abdominal lymph node metastasis.1 patient had intrahepatic recurrence plus abdominal lymph node metastasis and pulmonary metastasis.1 patient had abdominal lymph node metastasis plus pulmonary metastasis.3 patients abdominal pulmonary metastasis.2 patients had recurrence or metastasis with the site was uncertain.aAll patients who had tumor recurrence or metastasis.b19 patients had intrahepatic recurrence only. Table 3Patterns of recurrence or metastasis.Table 3ParameterHepatectomy group (n = 43)Total recurrence or metastasis, na32Types of recurrence or metastasiss, na Intrahepatic only19 Extrahepatic only4 Intrahepatic plus extrahepatic7 Uncertain2Site of recurrence or metastasiss, nab Intrahepatic recurrence26 Peritoneal spread3 Abdominal lymph node metastasis7 Pulmonary metastasis5 Uncertain24 patients had intrahepatic recurrence plus abdominal lymph node metastasis.2 patients had intrahepatic recurrence plus peritoneal spread.1 patient had peritoneal spread plus abdominal lymph node metastasis.1 patient had intrahepatic recurrence plus abdominal lymph node metastasis and pulmonary metastasis.1 patient had abdominal lymph node metastasis plus pulmonary metastasis.3 patients abdominal pulmonary metastasis.2 patients had recurrence or metastasis with the site was uncertain.aAll patients who had tumor recurrence or metastasis.b19 patients had intrahepatic recurrence only. Patterns of recurrence or metastasis. 4 patients had intrahepatic recurrence plus abdominal lymph node metastasis. 2 patients had intrahepatic recurrence plus peritoneal spread. 1 patient had peritoneal spread plus abdominal lymph node metastasis. 1 patient had intrahepatic recurrence plus abdominal lymph node metastasis and pulmonary metastasis. 1 patient had abdominal lymph node metastasis plus pulmonary metastasis. 3 patients abdominal pulmonary metastasis. 2 patients had recurrence or metastasis with the site was uncertain. All patients who had tumor recurrence or metastasis. 19 patients had intrahepatic recurrence only. Complications in the overall cohort The incidence of all-grade overall complications was 43/43 in the hepatectomy group and 35/35 in the TACE group (p = 1.000) (Table 4). The incidence of grade III/IV overall complications was 11/43 and 9/35, respectively (p = 0.989), with no significant difference observed between the groups. The number of all-grade hepatectomy-related complications was significantly lower than that of TACE-related complications (19/43 vs. 24/35, p = 0.031). The rates of grade III/IV complications related to hepatectomy and TACE were 5/43 and 5/35, respectively (p = 0.993). The rates of all-grade and grade III/IV complications related to immunotherapy in the hepatectomy and TACE groups were 42/43 vs. 35/35 (p = 1.000) and 9/43 vs. 8/35 (p = 0.838), respectively, with no significant differences between groups.Table 4Complications/AEs following hepatectomy or TACE.Table 4Complications/AEsAll grades (%)pIII/IV grades (%)pHepatectomy group (n = 43)TACE group (n = 35)Hepatectomy group (n = 43)TACE group (n = 35)Total, No. of patients43 (100)35 (100)1.00011 (24.4)9 (25.7)0.989Hepatectomy or TACE relevance, No. of patients19 (42.2)24 (68.6)0.0315 (11.6)5 (14.3)0.993Target immunotherapy relevance, No. of patients42 (97.7)35 (100)1.0009 (20.9)8 (22.9)0.838Hepatectomy or TACE relevance eventsaFever (> 38.5 °C, > 3 days)7 (16.3)5 (14.3)3 (7.0)1 (2.9)Pleural effusion/Ascites4 (9.3)6 (17.1)1 (2.3)2 (5.7)Intra-abdominal hemorrhage1 (2.3)0 (0.0)0 (0.0)0 (0.0)Postoperative liver failure†2 (4.7)1 (2.9)1 (2.3)0 (0.0)Bile leakage1 (2.3)0 (0.0)1 (2.3)0 (0.0)Pneumonia2 (4.7)1 (2.9)0 (0.0)0 (0.0)Wound infection1 (2.3)0 (0.0)0 (0.0)0 (0.0)Upper gastrointestinal bleeding1 (2.3)2 (5.7)0 (0.0)1 (2.9)Nausea and vomiting6 (13.3)15 (42.9)1 (2.3)3 (8.6)Others1 (2.3)2 (5.7)0 (0.0)0 (0.0)Target immunotherapy relevance eventsaHypertension20 (46.5)19 (54.3)3 (7.0)5 (14.3)Hand-foot skin reaction24 (55.8)21 (60.0)2 (4.7)2 (5.7)Diarrhea3 (7.0)5 (14.3)0 (0.0)0 (0.0)Fatigue5 (11.6)6 (17.1)0 (0.0)1 (2.9)Increased ALT40 (88.9)31 (88.6)9 (20.0)9 (25.7)Increased AST37 (82.2)30 (85.7)6 (13.3)6 (17.1)Increased TBIL35 (74.4)26 (74.3)5 (11.6)5 (14.3)Weight loss7 (16.3)7 (20.0)1 (2.3)2 (5.7)Thrombocytopaenia8 (17.8)5 (14.3)2 (4.7)2 (5.7)Others5 (11.6)4 (11.4)0 (0.0)0 (0.0)†: Defined by the “50-50” criterion on postoperative day 5 with a prothrombin time of < 50% and a total bilirubin of > 50 μmol/L.Abbreviations: AE, adverse event; TACE, transarterial chemoembolization; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin.aNumber of complications related to hepatectomy, TACE, or target immunotherapy are shown; in some cases, one patient had more than one complication. Table 4Complications/AEs following hepatectomy or TACE.Table 4Complications/AEsAll grades (%)pIII/IV grades (%)pHepatectomy group (n = 43)TACE group (n = 35)Hepatectomy group (n = 43)TACE group (n = 35)Total, No. of patients43 (100)35 (100)1.00011 (24.4)9 (25.7)0.989Hepatectomy or TACE relevance, No. of patients19 (42.2)24 (68.6)0.0315 (11.6)5 (14.3)0.993Target immunotherapy relevance, No. of patients42 (97.7)35 (100)1.0009 (20.9)8 (22.9)0.838Hepatectomy or TACE relevance eventsaFever (> 38.5 °C, > 3 days)7 (16.3)5 (14.3)3 (7.0)1 (2.9)Pleural effusion/Ascites4 (9.3)6 (17.1)1 (2.3)2 (5.7)Intra-abdominal hemorrhage1 (2.3)0 (0.0)0 (0.0)0 (0.0)Postoperative liver failure†2 (4.7)1 (2.9)1 (2.3)0 (0.0)Bile leakage1 (2.3)0 (0.0)1 (2.3)0 (0.0)Pneumonia2 (4.7)1 (2.9)0 (0.0)0 (0.0)Wound infection1 (2.3)0 (0.0)0 (0.0)0 (0.0)Upper gastrointestinal bleeding1 (2.3)2 (5.7)0 (0.0)1 (2.9)Nausea and vomiting6 (13.3)15 (42.9)1 (2.3)3 (8.6)Others1 (2.3)2 (5.7)0 (0.0)0 (0.0)Target immunotherapy relevance eventsaHypertension20 (46.5)19 (54.3)3 (7.0)5 (14.3)Hand-foot skin reaction24 (55.8)21 (60.0)2 (4.7)2 (5.7)Diarrhea3 (7.0)5 (14.3)0 (0.0)0 (0.0)Fatigue5 (11.6)6 (17.1)0 (0.0)1 (2.9)Increased ALT40 (88.9)31 (88.6)9 (20.0)9 (25.7)Increased AST37 (82.2)30 (85.7)6 (13.3)6 (17.1)Increased TBIL35 (74.4)26 (74.3)5 (11.6)5 (14.3)Weight loss7 (16.3)7 (20.0)1 (2.3)2 (5.7)Thrombocytopaenia8 (17.8)5 (14.3)2 (4.7)2 (5.7)Others5 (11.6)4 (11.4)0 (0.0)0 (0.0)†: Defined by the “50-50” criterion on postoperative day 5 with a prothrombin time of < 50% and a total bilirubin of > 50 μmol/L.Abbreviations: AE, adverse event; TACE, transarterial chemoembolization; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin.aNumber of complications related to hepatectomy, TACE, or target immunotherapy are shown; in some cases, one patient had more than one complication. Complications/AEs following hepatectomy or TACE. †: Defined by the “50-50” criterion on postoperative day 5 with a prothrombin time of < 50% and a total bilirubin of > 50 μmol/L. Abbreviations: AE, adverse event; TACE, transarterial chemoembolization; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin. Number of complications related to hepatectomy, TACE, or target immunotherapy are shown; in some cases, one patient had more than one complication. Discussion The prognosis for patients with spontaneously ruptured HCC is generally poor, with a reported mortality rate following spontaneous rupture as high as 24%.6 For these patients, TAE is the most commonly used emergency hemostatic measure. Patients may undergo TACE or hepatectomy following TAE to improve survival. However, in terms of long-term prognosis, patients with spontaneously ruptured HCC fare significantly worse than those without rupture.7,8,23 Consequently, improving the prognosis of patients with spontaneously ruptured HCC remains a significant clinical challenge and focus. Treatment modalities for spontaneously ruptured HCC typically include conservative management, TAE, TACE, and surgery,24 each carrying distinct adverse reaction profiles and prognostic implications. In the present study, all patients initially received TAE at a local hospital to achieve hemostasis. Patients were then treated with either hepatectomy or TACE combined with targeted therapy and immunotherapy. To minimize patient heterogeneity, our inclusion criteria required eligibility for radical surgical resection based on preoperative evaluation. Consequently, patients with intrahepatic multiple metastases or major vascular invasion accompanied by ruptured HCC bleeding were excluded. Our analyses revealed 1-, 3-, and 5-year OS rates of 80.8%, 40.1%, and 23.0%, respectively. This represents a significant improvement in prognosis compared with previously reported data for spontaneously ruptured HCC,9 suggesting that targeted therapy and immunotherapy can substantially enhance survival outcomes. Notably, the 1-, 3-, and 5-year OS rates in the hepatectomy group were 88.4%, 53.9%, and 31.8%. The 5-year OS rate of 31.8% achieved with hepatectomy combined with targeted therapy and immunotherapy is markedly higher than the previously reported rate of less than 20% in patients with ruptured HCC undergoing surgery alone.9 This benefit may be attributed to the ability of targeted therapy and immunotherapy to eliminate residual microscopic tumor cells post-surgery, thereby offering patients a genuine chance of cure and long-term survival. Furthermore, long-term survival in the TACE group was also significantly superior to previous reports of TACE treatment for spontaneously ruptured HCC.25,26 Our study also identified TACE as an independent risk factor for OS compared with hepatectomy. This indicated hepatectomy conferred a survival benefit over TACE for spontaneously ruptured HCC, a finding consistent with previous studies.24,27,28 This advantage likely stems from the radical nature of surgical resection. Similarly, hepatectomy significantly prolonged EFS compared with TACE. This finding was robust, as the same results were observed in the multivariate Cox analysis following PSM. The PSM-adjusted multivariate Cox analysis indicated that TACE (HR: 4.681, 95% CI: 2.235–9.807 for OS; HR: 5.785, 95% CI: 2.899–11.546 for EFS), AFP > 400 ng/mL (HR: 2.405, 95% CI: 1.238–4.673 for OS; HR: 2.136, 95% CI: 1.161–3.930 for EFS), and VI (HR: 3.205, 95% CI: 1.505–6.827 for OS; HR: 4.578, 95% CI: 2.117–9.898 for EFS) were independent risk factors for OS and EFS in patients with spontaneously ruptured HCC. Previous studies have reported VI and AFP > 400 ng/mL as independent risk factors for OS;23,28,29 our results corroborate that patients with VI or elevated AFP levels experience poorer OS and EFS. While larger tumor diameter has been reported as an independent risk factor for OS in spontaneously ruptured HCC,27,28 we did not find a significant association between tumor diameter and OS. This may be because of the high prevalence of large tumors in our cohort. The relatively small sample size combined with a substantial number of patients with large tumors may have limited the statistical power to detect differences in survival based on tumor size. Postoperative peritoneal dissemination is a critical factor contributing to the poor prognosis of spontaneously ruptured HCC.30,31 The reported rates of postoperative peritoneal dissemination in patients undergoing hepatectomy range from over 10%28,31 to as high as 30%.9 In the present study, the incidence of postoperative peritoneal dissemination was only 7.0% (3/43), which is considerably lower than rates reported in previous studies. This lower rate may be associated with the administration of adjuvant targeted therapy and immunotherapy following hepatectomy, suggesting that such therapy may help mitigate the risk of peritoneal recurrence. Regarding safety, we observed a higher overall complication rate following TACE and hepatectomy compared with those reported in previous reports.32,33 However, further analysis revealed no increase in complications in the hepatectomy group relative to the TACE group; hepatectomy-related complications were even less frequent than TACE-related complications. This may be explained by the fact that tumors often fail to achieve complete necrosis after TACE, necessitating multiple TACE sessions, which can lead to a cumulative increase in procedure-related complications. These findings suggest that, in terms of long-term safety, hepatectomy does not increase the risk of complications compared with TACE for patients with spontaneously ruptured HCC. Certainly, we originally planned to conduct further subgroup analyses based on the different targeted agents. However, given the relatively small sample size of this study, further subgrouping would result in even more limited sample sizes. This would lead to inadequate statistical power, potentially precluding any reliable conclusions. Besides, this study is limited by its retrospective design. As inherent limitations of a retrospective design, biases such as selection bias, information bias, and measurement bias are unavoidable. Future multi-center, prospective studies with larger sample sizes are warranted to further validate our findings. Conclusion Targeted therapy and immunotherapy can significantly improve the prognosis of patients with spontaneously ruptured HCC. Compared with TACE, hepatectomy is the optimal treatment for enhancing long-term prognosis and reducing the risk of peritoneal dissemination. Furthermore, hepatectomy does not increase the risk of complications compared with the cumulative risks associated with multiple TACE procedures. Therefore, for patients with spontaneously ruptured HCC, we recommend hepatectomy following TAE hemostasis and recovery of liver function, followed by adjuvant targeted therapy and immunotherapy. CRediT authorship contribution statement Jianwei Liu: Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. Xiaorong Pan: Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. Shilei Bai: Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. Caixia Lu: Methodology, Investigation, Data curation. Chunmei Li: Methodology, Investigation, Formal analysis, Data curation. Liu Liu: Project administration, Methodology, Investigation, Data curation. Jian Zhai: Methodology, Investigation, Formal analysis, Data curation. Hui Xue: Methodology, Investigation, Formal analysis, Data curation. Yong Xia: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Kui Wang: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Informed consent All patients provided written informed consent before participating and allowed the use of their clinicopathological data during diagnosis and treatment for medical research. Data availability statement The data supporting the findings of this study are available upon request from the corresponding author (wangkuiykl@163.com). The data are not publicly available due to privacy or ethical restrictions. Ethics statement This study was approved by the Ethics Committee of Eastern Hepatobiliary Surgery Hospital (the ethical approval number was EHBHKY2019-K-005). And it was carried out in accordance with the declaration of Helsinki. Organ donation Not applicable. Animal treatment Not applicable. Declaration of generative AI and AI-assisted technologies in the writing process None. Funding This study was funded by the Three-year Action Plan for Promoting Clinical Skills and Innovation Ability of Municipal Hospitals in Shanghai (grant number SHDC2020CR2038B); the Meng Chao Talents Leadership Reserve Training Plan (Kui Wang); the “Strong Sea” Innovation Team Program of Naval Military Medical University; and the Explorer Program of Shanghai Scientific and Technological Committee (grant number 21TS1400500); Scientific research project of Shanghai Municipal Health Commission (grant number 20234Y0151); Jiading District Health Commission 2025 Scientific Research Projects (2025-KY-JB-04); Naval Medical University Third Affiliated Hospital Departmental Project in 2025 - Clinical Research Cultivation Program (2025LC01); Tengfei Engineering Talent Cultivation Program of Third Affiliated Hospital of Naval Medical University (TF2024XSYJ04); Baoshan District Health Commission Outstanding Youth (Talent Development) Program (BSWSYC-2024-31); 2025 Shanghai Clinical Cohort Project—Reserve Clinical Cohort (SHDC2025CCS024), 2025 Shanghai Oriental Talent Program - Top-notch Project (BJWS2025062). Declaration of competing interest The authors declare the following financial interests, and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.